✦ LIBER ✦

Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

✍ Scribed by Tetsuya Mitsudomi

Book ID: 117785736
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 110 KB
Volume: 12
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70194-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib or Chemotherapy for Non–Small-

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

✍ Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 341 KB

Gefitinib or Chemotherapy for Non–Small-

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

✍ Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 341 KB

## Background: Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (egfr) is highly responsive to egfr tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of standard chemotherapy. ##

PCN7 COMPARATIVE EFFECTIVENESS ASSESSMEN

PCN7 COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER

✍ B. Schwander; J. de Castro Carpeño; D.F. Heigener; E. Wright; H.G. Bischoff; S. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

25 A retrospective analysis of patients

25 A retrospective analysis of patients with advanced EGFR mutated lung cancer treated with either first line erlotinib or gefitinib

✍ Thillai, K.; Soultati, A.; Montes, A.; Karapanagiotou, E.; Spicer, J.; Lal, R. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 49 KB

EGFR mutation status and prognosis for g

EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer

✍ Sasaki, Hidefumi; Endo, Katsuhiko; Mizuno, Kotaro; Yano, Motoki; Fukai, Ichiro; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 88 KB

NICE guidance on erlotinib for first-lin

NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer

✍ Bernice Dillon; Bhash Naidoo; Helen Knight; Peter Clark 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 44 KB